Skip to content

The Risk of Hypertension Associated With Oral Glucocorticoids in Chronic Inflammatory Diseases

The Risk of Hypertension Associated With Oral Glucocorticoids in Chronic Inflammatory Diseases in England.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03760562
Enrollment
111804
Registered
2018-11-30
Start date
1998-01-01
Completion date
2015-09-30
Last updated
2018-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Glucocorticoids are widely used for the treatment of chronic inflammatory diseases. In 2008, it was estimated that 0.8% of the United Kingdom adult population had used long-term (≥ 3 months) glucocorticoids, rising to 3% in women aged over 80 years. The aim of the project is to investigate the dose-response estimates of risk of high blood pressure associated with oral glucocorticoids.

Detailed description

Hypertension is a chronic condition which affects 1 in 5 of the world adult population. The cause of hypertension is unknown in about 95% of patients, whilst 5% are secondary to underlying adrenal disorders or other identifiable causes. Glucocorticoids are widely used for the treatment of chronic inflammatory diseases. In 2008, it was estimated that 0.8% of the UK adult population had used long-term (≥ 3 months) glucocorticoids, rising to 3% in women aged over 80 years. Glucocorticoids are effective in controlling underlying chronic inflammatory disease in majority of cases. However, their continuous use can result in a variety of complications, including hypertension.Although it is acknowledged that excess cortisol is a leading cause of hypertension, the role of exogenous glucocorticoids is less known. The aim of the project is to investigate the dose-response estimates of risk of high blood pressure associated with oral glucocorticoids. This is a retrospective cohort study of people diagnosed with at least one of six chronic inflammatory diseases (polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, vasculitis and inflammatory bowel disease). This study will be based on the analysis of existing primary care health records routinely collected, linked to hospital and mortality data.

Interventions

DRUGGlucocorticoids

Oral Glucocorticoids.

Sponsors

University of Leeds
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients aged 18 years old or over * Registered in a participating general practice 1 year or more during the study period * Minimum of 1 year prior to study entry meeting CPRD data quality * Diagnosed with at least one of the 6 chronic inflammatory diseases

Exclusion criteria

* Patients aged under 18 years during the study period * Registered in general practices that did not consent to data linkage

Design outcomes

Primary

MeasureTime frameDescription
Glucocorticoid-related hypertension18 yearsNumber of patients with incident hypertension

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026